You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,266,923


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,266,923
Title:Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets
Abstract: Provided herein are methods and compositions, including pharmaceutical compositions, for treating thrombosis, vascular inflammation, and thrombocytopenia. The methods and compositions of the present invention are also useful for extending the useful storage shelf life of platelets.
Inventor(s): Shaw; Gray D. (Milton, MA)
Assignee:
Application Number:13/168,048
Patent Claims:1. A cyclic conjugated peptide (CCP) comprising the amino acid sequence Ala-Cys-Thr-Glu-Arg-Met-Ala-Leu-His-Asn-Leu-Cys-Gly-Gly-Lys, (SEQ ID NO: 4), wherein the C-terminal lysine residue is covalently linked with a polymeric compound and wherein said CCP has the ability to bind in a non-covalent manner to human GPIb.alpha., and said CCP exhibits more potent inhibition of platelet binding to Mac-1 integrin receptors compared to a cyclic peptide comprising the same amino acid sequence, without a covalently linked polymeric compound.

2. The cyclic conjugated peptide of claim 1, wherein the polymeric compound is a polyethylene glycol.

3. The cyclic conjugated peptide of claim 2, wherein the polyethylene glycol has a molecular weight of between 300 and 50,000 daltons.

4. A method for increasing the useful storage life of platelets, said method comprising storing platelets with the cyclic conjugated peptide (CCP) of claim 1; wherein said CCP has the ability to bind in a non-covalent manner to human GPIb.alpha., and said CCP exhibits more potent inhibition of platelet binding to Mac-1 integrin compared to a cyclic peptide comprising the same amino acid sequence, without a covalently linked polymeric compound.

5. The method of claim 4, wherein the platelets are stored at temperatures below 22.degree. C.

6. The method of claim 4, wherein the platelets are stored at temperatures of from about 0.degree. C. to about 4.degree. C.

7. A method of treating a disorder selected from the group consisting of thrombosis, vascular inflammation, and thrombocytopenia, the method comprising administering a CCP of claim 1 to a human subject.

8. A method of claim 7 wherein the CCP is administered in combination with a molecule selected from the group consisting of a VWF antagonist and a TPO mimetic.

9. The method of claim 8, wherein the VWF antagonist is selected from the group consisting of AJW200, ARC-1779, ALX-0081, ALX-0681, GPG-290 or GPIb.alpha.-Ig variant fusion polypeptides.

10. The method of claim 8, wherein the TPO mimetic is selected from the group consisting of PROMACTA.RTM. (eltrombopag) (GlaxoSmithKline, Inc.) and NPLATE.RTM. (romiplostim) (Amgen, Inc.).

11. A cyclic conjugated peptide (CCP) comprising the amino acid sequence Ala-Cys-Thr-Glu-Arg-Met-Ala-Leu-His-Asn-Leu-Cys-Gly-Gly-Lys, (SEQ ID NO: 4), wherein the C-terminal lysine residue is covalently linked with a polymeric compound and wherein said CCP has the ability to bind in a non-covalent manner to GPIb.alpha., and said CCP exhibits more potent inhibition of platelet phagocytosis by cells expressing Ashwell-Morell asialoglycoprotein receptors compared to a cyclic peptide comprising the same amino acid sequence, without a covalently linked polymeric compound.

12. The CCP of claim 11, wherein the polymeric compound is a polyethylene glycol.

13. The CCP of claim 12, wherein the polyethylene glycol has a molecular weight of between 300 and 50,000 daltons.

14. A method for increasing the useful storage life of platelets, said method comprising storing platelets with the cyclic conjugated peptide (CCP) of claim 11; wherein said CCP has the ability to bind in a non-covalent manner to human GPIb.alpha., and said CCP exhibits more potent inhibition of platelet phagocytosis by cells expressing Ashwell-Morell asialoglycoprotein receptors compared to a cyclic peptide comprising the same amino acid sequence, without a covalently linked polymeric compound.

15. The method of claim 14, wherein the platelets are stored at temperatures below 22.degree. C.

16. The method of claim 14, wherein the platelets are stored at temperatures of from about 0.degree. C. to about 4.degree. C.

17. A method of treating a disorder selected from the group consisting of thrombosis, vascular inflammation, and thrombocytopenia, the method comprising administering a CCP of claim 11 to a human subject.

18. A method of claim 17 wherein the CCP is administered in combination with a molecule selected from the group consisting of a VWF antagonist and a TPO mimetic.

19. The method of claim 18, wherein the VWF antagonist is selected from the group consisting of AJW200, ARC-1779, ALX-0081, ALX-0681, GPG-290 or GPIb.alpha.-Ig variant fusion polypeptides.

20. The method of claim 18, wherein the TPO mimetic is selected from the group consisting of PROMACTA.RTM. (eltrombopag) (GlaxoSmithKline, Inc.) and NPLATE.RTM. (romiplostim) (Amgen, Inc.).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.